{
  "nct_id": "NCT02296775",
  "title": "Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis",
  "conditions": [
    "Rheumatoid Arthritis"
  ],
  "interventions": [
    "DRL_RI",
    "Rituxan",
    "MabThera"
  ],
  "phase": "PHASE1",
  "summary": "This study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\\_RI or one of two sources of rituximab (Rituxan\u00ae or MabThera\u00ae). Patients will also be monitored for safety, B cell depletion and recovery, and for the development of immune responses to the administered study drugs",
  "source": "clinicaltrials.gov",
  "collected_at": "2026-01-07T20:03:08.891551"
}